Skip to main content

Published locations for Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations

User login

  • Reset your password
  • /content/enasidenib-monotherapy-responses-37-relapsed/refractory-aml-and-idh2-mutations
  • /hematologynews/article/142331/aml/enasidenib-monotherapy-responses-37-relapsed/refractory-aml-and
  • /oncologypractice/article/142331/aml/enasidenib-monotherapy-responses-37-relapsed/refractory-aml-and
  • /hematology-oncology/article/142331/aml/enasidenib-monotherapy-responses-37-relapsed/refractory-aml